论文部分内容阅读
近年来研究表明,异常免疫介导的造血抑制是再生障碍性贫血(AA)的主要病理机制[1-2]。免疫异常在AA发病因素中起着至关重要的作用。免疫抑制剂已经成为治疗AA的主要药物。粒-巨噬细胞集落刺激因子(GM-CSF)、环孢素A(CsA)及康力龙(Slamozolum)(GCS方案)治疗
In recent years, studies have shown that abnormal immune-mediated hematopoietic suppression is the main pathological mechanism of aplastic anemia (AA) [1-2]. Immune abnormalities play a crucial role in the pathogenesis of AA. Immunosuppressants have become the main drug for the treatment of AA. Granulocyte-macrophage colony-stimulating factor (GM-CSF), cyclosporine A (CsA) and Slamozolum (GCS regimen)